Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

NCT05191797 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Closed per SRC Low Accrual Policy

Conditions

Extensive Stage Lung Small Cell Carcinoma
Limited Stage Lung Small Cell Carcinoma

Interventions

DRUG: Bomedemstat
BIOLOGICAL: Atezolizumab

Sponsor

University of Washington

Collaborators

[object Object]
[object Object]